Polyclonal and monoclonal actin antibodies

PP242, INK128 and AZD8055 were purchased from Active Biochem (Maplewood, NJ). Torin 1 was purchased from Tocris (Bristol, UK). The GSK3 inhibitor SB216763, the proteasome inhibitor MG132 and the protein synthesis inhibitor cycloheximide (CHX) were purchased from Sigma Chemical Co. (St. Louis, MO). The NEDD8-activating enzyme inhibitor MLN4924 was provided by Millennium Pharmaceuticals, Inc (Cambridge, MA). Cyclin D1, p-GSK3α/β (S21/9), p-AKT (S473), AKT, p-S6 (S235/236), and S6 antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA). GSK3α/β antibody was purchased from Upstate/EMD Millipore (Billerica, MA). Polyclonal rictor and raptor antibodies were purchased from Bethyl Laboratories, Inc. (Montgomery, TX). Both polyclonal and monoclonal actin antibodies were purchased from Sigma Chemical Co. Myc-tagged constitutively active form of GSK3β (GSK3βCA) (24 (link)) was provided by Dr. Binhua P. Zhou (The University of Kentucky, College of Medicine, Lexington, Kentucky). Flag-cyclin D1 expression plasmid was provided by Dr. Alan Diehl (Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA). Myc-Rictor and HA-raptor expression plasmids were purchased from Addegene (Cambridge MA).